Bolland M, et al. - Among HIV-infected men who received two annual 4mg doses of zoledronate in a prior two-year randomized placebo-controlled trial, researchers investigated if the impacts on bone mineral density (BMD) and the anti-resorptive effects endured beyond ten years. All participants in the original trial known to be alive and living in New Zealand were invited to take part in this study, 11 years after their second dose of study medication. They assessed BMD at the lumbar spine, proximal femur and total body, and markers of bone turnover as outcome measures. Participants were followed-up, on average, for 12.4 years. A higher BMD was seen in the zoledronate group vs the placebo group at the final visit. In men, bone turnover and BMD were influenced by two annual 4mg doses of zoledronate; these effects endured for at least 11 years after the second dose.